Familial adenomatous polyposis (FAP) is a rare inherited disorder characterized by the growth of numerous polyps in the colon and rectum, which can lead to colorectal cancer if untreated. It accounts for approximately 1% of colorectal cancer cases, with an estimated incidence of 1 in 5,000 to 1 in 18,000, affecting men and women equally. There is a high unmet clinical need for better therapies, as current treatment options, such as surgery and NSAIDs, have limitations. Increasing research on novel familial adenomatous polyposis therapeutics, including chemo-preventive agents and gene therapies, is driving pipeline growth in the coming years.
Major companies involved in the familial adenomatous polyposis pipeline drugs market include Rapamycin Holdings Inc., Recursion Pharmaceuticals Inc., and others.
Leading drugs currently in the pipeline include Encapsulated Rapamycin, REC-4881, and others.
Increasing research on novel therapeutics, advancements in gene therapies, and efforts to address high unmet clinical needs are driving the familial adenomatous polyposis pipeline growth.
The Familial Adenomatous Polyposis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into familial adenomatous polyposis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Familial Adenomatous Polyposis. The familial adenomatous polyposis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The familial adenomatous polyposis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with familial adenomatous polyposis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to familial adenomatous polyposis.
Familial adenomatous polyposis (FAP) is a rare, inherited disorder causing numerous polyps in the colon and rectum, which can develop into colorectal cancer if untreated. It results from mutations in the adenomatous polyposis coli (APC) gene, affecting cell growth regulation and leading to uncontrolled polyp formation. It typically emerges in adolescence, with cancer risks increasing by adulthood without intervention.
Familial adenomatous polyposis treatment aims to prevent cancer progression. Prophylactic colectomy, removing the colon, is a primary intervention. Regular endoscopic surveillance helps to monitor polyp growth. The use of nonsteroidal anti-inflammatory drugs (NSAIDs), such as celecoxib, reduces polyp numbers. Genetic counseling is beneficial for affected families, while emerging therapies, such as targeted molecular treatments, provide better outcomes.
Familial Adenomatous Polyposis (FAP) is the second most common inherited polyposis syndrome, with an estimated incidence ranging from 1 in 5,000 to 1 in 18,000, affecting both men and women equally. It occurs in 1 in 10,000 to 1 in 30,000 live births and accounts for less than 1% of colorectal cancer cases in the United States. Epidemiological studies indicate a prevalence of 1 in 8,300 in the United Kingdom and 1 in 17,400 in Japan.
This section of the report covers the analysis of familial adenomatous polyposis drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total familial adenomatous polyposis clinical trials.
The drug molecule categories covered under the familial adenomatous polyposis pipeline analysis include small molecules, monoclonal antibodies, gene therapies, RNA-based therapies, immunotherapies, and others. The familial adenomatous polyposis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for familial adenomatous polyposis.
The EMR report for the familial adenomatous polyposis drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed familial adenomatous polyposis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in familial adenomatous polyposis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for Familial Adenomatous Polyposis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of familial adenomatous polyposis drug candidates.
Celecoxib, a COX-2 inhibitor, reduces polyp growth, while metformin, an anti-diabetic drug, suppresses tumorigenesis via the mTOR pathway. Yonsei University is sponsoring a Phase III clinical trial to assess the chemopreventive effect of celecoxib and metformin in patients with familial adenomatous polyposis. The study, involving approximately 100 participants, is expected to conclude by December 2025.
Encapsulated Rapamycin (eRapa), developed by Rapamycin Holdings Inc., is under Phase IIa evaluation for reducing polyp burden in familial adenomatous polyposis (FAP) patients. eRapa is an oral mTOR inhibitor and uses nanotechnology for enhanced bioavailability. The 24-month trial will enroll around 30 participants and will examine dose efficacy and food effect, with completion expected in 2025.
REC-4881 is an orally bioavailable, non-ATP-competitive MEK1/2 inhibitor designed to reduce polyp burden and prevent adenocarcinoma progression in FAP patients. Developed by Recursion Pharmaceuticals Inc., it is currently being assessed in a Phase I/II clinical trial, focusing on its efficacy, safety, pharmacokinetics, and pharmacodynamics. With FDA orphan drug designation, REC-4881 demonstrates a favorable gut-localized PK profile. The study is estimated to enroll approximately seven participants and is expected to conclude in 2025.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Familial Adenomatous Polyposis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for familial adenomatous polyposis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into familial adenomatous polyposis collaborations, regulatory environments, and potential growth opportunities.
Global Colorectal Cancer Therapeutics Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share